Bissonnette, Robert
Gottlieb, Alice B.
Langley, Richard G.
Leonardi, Craig L.
Papp, Kim A.
Pariser, David M.
Uy, Jonathan
Lafferty, Kim Parnell
Langholff, Wayne
Fakharzadeh, Steven
Berlin, Jesse A.
Brouwer, Emily S.
Greenspan, Andrew J.
Strober, Bruce E.
Article History
Accepted: 19 March 2021
First Online: 2 June 2021
Declarations
:
: PSOLAR was supported by Janssen Scientific Affairs, LLC.
: Robert Bissonnette is an Advisory Board Member, Consultant, Speaker, Investigator for, and/or received honoraria or grants from AbbVie, Almirall, Anaptys Bio, Arcutis, Arista, Bausch Health/Valeant, Boehringer Ingelheim, Boston Pharma, Bristol-Myers Squibb, Dermavant, Eli Lilly, Escalier, Janssen, Kineta, Kyowa Kirin, LEO Pharma, Pfizer, Regeneron, Sienna and UCB. Alice B. Gottlieb has received honoraria as an advisory board member and consultant for Avotres Therapeutics, Belersdorf, Boehringer Ingelheim, Bristol-Meyers Squibb Co., Incyte, Janssen, Leo Pharma, Eli Lilly, Novartis, Sun Pharmaceutical Industries, Inc., UCB, and Xbiotech (only stock options that she has not used); and has received research/educational grants from Boehringer Ingelheim, Incyte, Janssen, Novartis, UCB, Xbiotech, and Sun Pharma. Richard G. Langley has received honoraria or grants as principal investigator, scientific advisory board member, and lecturer for AbbVie, Amgen, Celgene, Leo, Merck, Novartis, and Pfizer; and as principal investigator and scientific advisory board member for Boehringer Ingelheim, Lilly, and UCB. Craig L. Leonardi has received honoraria or grants as an consultant/advisory board member for AbbVie, Amgen, Boehringer-Ingelheim, Dermira, Eli Lilly, Janssen, Leo, Pfizer, Sandoz, UCB and Vitae; as an investigator for Actavis, AbbVie, Allergan, Amgen, Boehringer-Ingelheim, Celgene, Coherus, Cellceutix, Corrona, Dermira, Eli Lilly, Galderma, Glenmark, Janssen, Leo Pharma, Merck, Novartis, Novella, Pfizer, Sandoz, Sienna, Stiefel, UCB and Wyeth; and as a speaker for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Ortho Dermatologics, Sun Pharmaceuticals, and UCB. Kim A. Papp has received honoraria and/or grants from AbbVie, Akros, Amgen, Arcutis, Astellas, AstraZeneca, Avilion, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Canfite, Celgene, Centocor, Coherus, Dermira, Dow Pharma, Eli Lilly and Company, Forward Pharma, Galderma, Genentech, Gilead, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, LEO, MedImmune, Meiji Seika Pharma, Merck (MSD), Merck-Serono, Mitsubishi Pharma, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi Aventis/Genzyme, Samsung Bioepsis, Sun Pharma, Takeda, UCB Pharma, and Valeant/Bausch Health. David M. Pariser has received honoraria or grants/research funding as an investigator at Abbott Laboratories, Almirall, Amgen, AOBiome LLC, Asana Biosciences LLC, Bickel Biotechnology, Celgene Corporation, Dermavent Sciences, Dermira, Eli Lilly and Co., Leo Pharma, Menlo Therapuetics, Merck & Co., Novartis Pharmaceuticals, Novo Nordisk A/S, Ortho Dermatologics, Pfizer Inc., Regeneron, Stiefel (a GSK company), and Valeant Pharmaceuticals International; as an consultant at Atacama Therapeutics, Bickel Biotechnology, Biofrontera AG, BMS, Celgene, Dermira, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi, TDM SurgiTech, TheraVida, and Valeant Pharmaceuticals International; as an advisory board member at Pfizer; and as a Data Safety Monitoring Board member at BMS. Jonathan Uy, Kim Parnell Lafferty, Wayne Langholff, Steven Fakharzadeh, Emily S. Brouwer, and Andrew J. Greenspan are employees of Janssen, of which Johnson & Johnson is the parent company, and own stock or stock options in Johnson & Johnson. Jesse A. Berlin is an employee of Johnson & Johnson and owns stock or stock options in Johnson & Johnson. Bruce E. Strober has received honoraria or research grants as a consultant for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Boehringer Ingelheim, Bristol-Myers-Squibb, Celgene, Dermavant, Dermira, Equillium, Janssen, Leo, Eli Lilly, Meiji Seika Pharma, Mindera, Novartis, Pfizer, GlaxoSmithKline, UCB Pharma, Sun Pharma, Ortho Dermatologics, Regeneron, and Sanofi-Genzyme; as a speaker for AbbVie, Amgen, Eli Lilly, Janssen, and Ortho Dermatologics; as scientific director for the Corrona Psoriasis Registry; as an investigator for Dermavant, AbbVie, Corrona Psoriasis Registry, Dermira, Cara, and Novartis; and as Editor-in-Chief at the <i>Journal of Psoriasis and Psoriatic Arthritis.</i>
: The registry protocol was approved by an Institutional Review Board or Ethics Committee at all study sites.
: Written informed consent was provided by all patients before participating in the study.
: All authors approved the final version of the manuscript and agreed to submit for publication.
: The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at ExternalRef removed.
: Not applicable.
: RB, RGL, CLL, KAP, DMP, WL, and BS contributed to the study conception and design of the registry. KAP and WL led the data collection and analysis. All authors drafted the text and/or provided critical review of drafts and approved the final manuscript.